PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
11.78%
Revenue growth 50-75% of CRWV's 23.55%. Martin Whitman would scrutinize if slower growth is temporary.
No Data
No Data available this quarter, please select a different quarter.
11.78%
Gross profit growth below 50% of CRWV's 25.15%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-273.15%
EBITDA decline while CRWV shows 33.05% growth. Joel Greenblatt would examine position.
-254.90%
EBITDA margin decline while CRWV shows 7.69% growth. Joel Greenblatt would examine position.
-273.15%
Operating income decline while CRWV shows 169.93% growth. Joel Greenblatt would examine position.
-254.90%
Operating margin decline while CRWV shows 156.60% growth. Joel Greenblatt would examine position.
273.15%
Other expenses growth while CRWV reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.00%
EPS decline while CRWV shows 23.08% growth. Joel Greenblatt would examine position.
-50.00%
Diluted EPS decline while CRWV shows 23.08% growth. Joel Greenblatt would examine position.
0.68%
Share count reduction exceeding 1.5x CRWV's 20.32%. David Dodd would verify capital allocation.
0.68%
Diluted share reduction exceeding 1.5x CRWV's 20.32%. David Dodd would verify capital allocation.